New HPV Therapy Trial Aims to Replace 'Watchful Waiting' for Women

GAITHERSBURG, MD – May 19, 2026

Amplexd Therapeutics, a clinical-stage biotechnology company, today announced the initiation of a Phase 2 clinical trial in Hong Kong for a novel therapy targeting precancerous cervical lesions caused by high-risk human papillomavirus (hr-HPV). The trial evaluates a self-administered treatment that could represent a significant shift away from the current standard of care, often described as 'watchful waiting,' which leaves millions of women in a state of prolonged anxiety and uncertainty.

The randomized, placebo-controlled study will assess the safety and efficacy of a proprietary suppository designed for early, non-surgical intervention. This move addresses a long-standing gap in women's health, where treatment options for low-grade cervical abnormalities have been notably limited, forcing patients and doctors into a passive monitoring phase or toward invasive procedures.

From Green Tea to a Potential Medical Breakthrough

The investigational therapy’s active ingredient is epigallocatechin gallate (EGCg), a potent bioactive compound most famously found in green tea. While the polyphenol has been a subject of health interest for decades, Amplexd has developed it into a proprietary, shelf-stable pharmaceutical formulation designed for targeted delivery as a vaginal suppository.

The scientific rationale for using EGCg is built on a growing body of preclinical and clinical research. Studies have shown that EGCg can directly interfere with the HPV life cycle. Its mechanism of action is believed to involve the suppression of E6 and E7, the viral oncoproteins that drive the development of cervical lesions and cancer. By promoting the breakdown of these proteins, EGCg helps inhibit the proliferation of infected cells and can induce apoptosis, or programmed cell death.

Furthermore, research suggests EGCg may bolster the body's own defenses by stimulating innate antiviral immune pathways. Previous independent clinical studies exploring various EGCg-based formulations have reported promising results, with some showing HPV clearance rates as high as 85% and significant regression of cervical lesions. Amplexd's trial aims to build on this foundation with a standardized, self-administered product designed for widespread accessibility.

Addressing a Critical Unmet Need in Women's Health

Globally, high-risk HPV is responsible for over 99% of cervical cancer cases. While Pap and HPV tests are effective screening tools, they also reveal a vast number of low-grade abnormalities, such as Atypical Squamous Cells of Undetermined Significance (ASC-US) and Low-Grade Squamous Intraepithelial Lesions (LSIL). In the United States alone, approximately 5% of cervical screenings show such abnormalities.

For these women, the diagnosis often marks the beginning of a stressful journey. The standard protocol is typically 'watchful waiting,' involving more frequent screenings over months or years to see if the lesions regress on their own or progress to a more severe stage. This period of surveillance is fraught with psychological and emotional distress for patients.

“These lesions are typically managed through increased surveillance known as ‘watchful waiting’ rather than active treatment, while advanced disease stages often require surgical interventions that are not uniformly accessible across healthcare settings,” said Alia Rahman, Chief Executive Officer of Amplexd, in the company's press release. “Despite the meaningful psychosocial and financial burdens associated with this approach, therapeutic advancements have been limited, and a significant unmet medical need for localized, non-surgical therapies remains.”

Amplexd's therapy is designed to fill this void by offering an active treatment option at the earliest stages. A non-surgical, self-administered approach could empower patients, reduce the need for frequent and costly follow-up appointments, and potentially prevent the progression to higher-grade dysplasia that necessitates invasive surgical procedures like LEEP or cone biopsies, which carry their own risks, including to future pregnancies.

A Global Fight Launched from a Strategic Hub

The decision to conduct the Phase 2 trial in Hong Kong underscores the global nature of the fight against cervical cancer, which remains the fourth most common cancer in women worldwide. The trial, authorized by the Hong Kong Department of Health, is being conducted at The Chinese University of Hong Kong in collaboration with Prince of Wales Hospital.

Hong Kong presents a strategic location for clinical research. Its regulatory framework adheres to high international standards, ensuring that data generated there is widely accepted by agencies like the U.S. Food and Drug Administration (FDA) and European regulators. The region boasts world-class medical expertise and infrastructure, coupled with strong intellectual property protection. This environment makes it an attractive hub for biotech companies looking to conduct rigorous clinical trials efficiently.

The local need is also apparent. In 2023, cervical cancer was the seventh most common cancer among women in Hong Kong, with 576 new cases diagnosed. While screening programs are in place, an effective early-stage treatment could significantly reduce the burden on the healthcare system and improve patient outcomes.

The Path Forward for Amplexd Therapeutics

Amplexd Therapeutics, founded in 2022, is a young company driven by a patient-centric mission. Its CEO, Alia Rahman, is a patient-scientist whose own 15-year experience with dysplasia reportedly fuels the company’s focus on creating accessible, non-invasive solutions. The company recently secured $2 million in funding from an Asia-based family office, providing the capital to advance its clinical programs.

The Phase 2 trial will enroll women diagnosed with ASC-US and LSIL who have a confirmed hr-HPV infection. Researchers will evaluate key endpoints including the rate of lesion regression, viral clearance, and the overall safety profile of the investigational therapy. Recruitment for the study is currently underway, with initial clinical data anticipated in the first quarter of 2027.

More information about the study is publicly available on the U.S. National Library of Medicine's database under the trial identifier NCT07572396. While this trial represents a hopeful step forward, the company notes that its investigational therapy has not yet been approved by the FDA or any other regulatory body, and its ultimate safety and efficacy are not yet established. If successful, however, this EGCg-based therapy could pioneer a new standard of care, transforming the experience for millions of women diagnosed with early-stage HPV-related disease worldwide.